PROGRESS IN PRIMARY ALDOSTERONISM: Mineralocorticoid antagonist treatment for aldosterone-producing adenoma
- 1 March 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (3) , R125-R129
Abstract
Mineralocorticoid receptor antagonists have been used in patients with aldosterone-producing adenomas (APAs) as a test designed to predict the blood pressure (BP) outcome of surgery. They are commonly used in patients undergoing adrenalectomy to reduce BP and increase plasma potassium levels during the preoperative period. A small number of studies have compared the effects of surgery and mineralocorticoid antagonists either on BP, on serum potassium levels, or on the incidence of cardiovascular and renal outcomes in patients with primary aldosteronism with or without an APA; these studies found no difference between the two therapeutic options. Mineralocorticoid receptor antagonists can be used as a maintenance treatment for patients with APAs, who are judged to be poor operative risks or who do not want to undergo surgery.Keywords
This publication has 35 references indexed in Scilit:
- Outcomes of Adrenalectomy in Patients with Unilateral Primary Aldosteronism: A ReviewHormone and Metabolic Research, 2012
- Spontaneous remission of idiopathic aldosteronism after long‐term treatment with spironolactone: results from the German Conn’s RegistryClinical Endocrinology, 2011
- Mineralocorticoid Antagonists Treatment Versus Surgery in Primary AldosteronismHormone and Metabolic Research, 2010
- Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronismExpert Opinion on Pharmacotherapy, 2008
- Spontaneous Resolution of Idiopathic Aldosteronism After Long-Term Treatment With Potassium CanrenoateHypertension, 2007
- The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin RatioCirculation, 2007
- Role of Aldosterone Blockade for Treatment of Heart Failure and Post–Acute Myocardial InfarctionThe American Journal of Cardiology, 2006
- Antihypertensive Effects of Drospirenone With 17β-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 HypertensionCirculation, 2005
- Efficacy and tolerance of spironolactone in essential hypertensionThe American Journal of Cardiology, 1987
- THE METABOLISM AND BIOPHARMACEUTICS OF SPIRONOLACTONE IN MANDrug Metabolism and Drug Interactions, 1987